cytarabine has been researched along with 10-propargyl-10-deazaaminopterin in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Gardner, J; Gonen, M; Heaney, M; O'Connor, OA; Sirotnak, F; Smith, EA; Teruya-Feldstein, J; Toner, LE; Vrhovac, R | 1 |
Beltran, BE; Conlon, K; Cook, L; Dwyer, K; Feldman, T; Fields, PA; Gonsky, J; Hermine, O; Horwitz, SM; Humphrey, J; Kurman, M; Leoni, M; Moriya, J; Pereira, J; Phillips, AA; Ramos, JC; Sawas, A; Taylor, GP; Wandroo, F | 1 |
1 review(s) available for cytarabine and 10-propargyl-10-deazaaminopterin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for cytarabine and 10-propargyl-10-deazaaminopterin
Article | Year |
---|---|
Mogamulizumab
Topics: Adult; Aged; Aged, 80 and over; Aminopterin; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Deoxycytidine; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; International Agencies; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Oxaliplatin; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2019 |
1 other study(ies) available for cytarabine and 10-propargyl-10-deazaaminopterin
Article | Year |
---|---|
The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma.
Topics: Aminopterin; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cytarabine; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Gemcitabine; Humans; In Vitro Techniques; Lymphoma, Non-Hodgkin; Methotrexate; Mice; Mice, SCID; Time Factors; Xenograft Model Antitumor Assays | 2006 |